Real-World Studies
Low AP2M1 linked to anti-EGFR benefit in colorectal cancer trial cohort
Arai et alOncogene

In a study evaluating transcriptomic data from 15,025 colorectal cancer (CRC) tumors, researchers assessed gene expression signatures of clathrin-mediated endocytosis (CME) and the endosomal sorting complexes required for transport (ESCRT) pathway across consensus molecular subtypes (CMS) and oncogenic pathways. Expression of CME and ESCRT pathways varied across subtypes, showing the highest expression in CMS4 tumors and the lowest in CMS3 tumors. Furthermore, endocytosis signatures correlated with several key oncogenic signaling programs, specifically MAPK, TGF-β, WNT, PI3K, NOTCH, and angiogenesis.
When evaluating individual endocytosis-related genes for clinical relevance in the randomized phase III CALGB/SWOG 80405 trial cohort, low expression of AP2M1, a core adaptor within the CME complex, was significantly associated with longer overall survival and progression-free survival among patients treated with anti-EGFR agents. This predictive association was not observed in patients receiving anti-VEGF agents. The authors conclude that endocytic trafficking reflects biologically relevant tumor heterogeneity, links to oncogenic signaling, and may help guide therapeutic stratification for patients with metastatic CRC.
Key Takeaways
- In the randomized phase III CALGB/SWOG 80405 trial, low expression of the clathrin-mediated endocytosis core adaptor AP2M1 was significantly associated with longer overall survival and progression-free survival in patients treated with anti-EGFR therapy, an association not observed in patients receiving anti-VEGF therapy.
- Across 15,025 colorectal cancer tumors, expression of clathrin-mediated endocytosis and ESCRT pathways differed by consensus molecular subtype—with highest levels in CMS4 and lowest in CMS3—and correlated with multiple oncogenic signaling pathways including MAPK, TGF-β, WNT, PI3K, NOTCH, and angiogenesis.
Read the original sourceOncogene
